Evidence map›Paper›PMID 42716939›Full record

ArticleNature communications2026

Identification and validation of a previously missed mutational signature in colorectal cancer.

Mariya Kazachkova, Burçak Otlu, Marcos Díaz-Gay, Ammal Abbasi, Sarah Moody, Zichen Jiang, Sandra Perdomo, David C Wedge, Paul Brennan, Michael R Stratton and 1 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Mariya KazachkovaBiomedical Sciences Graduate Program, University of California San Diego, La Jolla, CA, USA.
Burçak OtluDepartment of Health Informatics, Graduate School of Informatics, Middle East Technical University, Ankara, Turkey.
Marcos Díaz-GayDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-0658-0467
Ammal AbbasiDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0009-0007-2836-4657
Sarah MoodySomatic Genomics Programme, Wellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0003-4904-1041
Zichen JiangDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Sandra PerdomoGenomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.ORCID http://orcid.org/0000-0001-7740-8141
David C WedgeManchester Cancer Research Centre, University of Manchester, Manchester, UK.ORCID http://orcid.org/0000-0002-7572-3196
Paul BrennanGenomic Epidemiology Branch, International Agency for Research on Cancer (IARC/WHO), Lyon, France.
Michael R StrattonSomatic Genomics Programme, Wellcome Sanger Institute, Cambridge, UK.ORCID http://orcid.org/0000-0001-6035-153X
Ludmil B AlexandrovBiomedical Sciences Graduate Program, University of California San Diego, La Jolla, CA, USA. L2alexandrov@health.ucsd.edu.ORCID http://orcid.org/0000-0003-3596-4515

Funding

Detecting Mutational Signatures of Environmental Mutagens in Heathy Individuals for Personalized Cancer PreventionR01ES032547 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ALEXANDROV, LUDMIL B · 2021 to 2025
$3.4M
Mapping immuno-genomic drivers of the head and neck precancer invasive-disease transitionU01CA290479 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ludmil B Alexandrov, Jorge Silvio Gutkind · 2023 to 2026
$3.1M
Understanding the origins of the mutational landscape in cancerR01ES036931 · NIEHS · UNIV OF ARKANSAS FOR MED SCIS · PI Ludmil B Alexandrov, Gunnar Boysen · 2025 to 2026
$1.5M
Exploring the Impact of Base Deaminase Deregulation on Precancer EvolutionR01CA296974 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ludmil B Alexandrov, Catriona Helen Macleod Jamieson · 2025 to 2026
$890k
Cancer Research UK (CRUK) C1994/A28701DH | NIHR | Health Services Research Programme (NIHR Health Services Research Programme) NIHR203308NCI NIH HHS R01 CA296974NCI NIH HHS U01 CA290479NIEHS NIH HHS R01 ES032547NIEHS NIH HHS R01 ES036931U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA296974U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U01CA290479U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) R01ES032547U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) R01ES036931
6 · The paper itself

Abstract

Mutational signature analysis has enhanced our understanding of mutagenic processes. In a recent study, we analyzed 802 microsatellite-stable colorectal cancers (CRC) and identified a de novo signature, SBS_D, which was decomposed into SBS18. Here, we re-evaluate this decomposition and provide evidence that SBS_D represents a distinct mutational process from SBS18. Through an analysis of 2,616 CRCs across three independent cohorts, we demonstrate that SBS_D is consistently present, suggesting this signature may have been previously overlooked. We illustrate that the pattern of SBS_D better aligns with signatures associated with deficiencies in DNA repair, despite evidence that SBS_D is not driven by canonical defects in these DNA repair pathways. Overall, this study identifies a previously unrecognized mutational signature in DNA repair-proficient CRC and proposes that its etiology may be linked to DNA repair infidelity emerging late in tumor development. SBS_D has been submitted to the COSMIC database and provisionally designated as SBS111.

Indexed as

Colorectal NeoplasmsMutationDNA Mutational AnalysisDNA RepairHumansMicrosatellite InstabilityMicrosatellite Repeats

Identifiers

PMID42716939
PMCPMC13558705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.